Rezolute, Inc.

RZLTSEC EDGAR

Pharmaceutical Preparations(NV)CIK: 1509261

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$55.7M	$43.8M	$32.5M	$15.0M	$14.4M
Operating Expenses	$70.4M	$56.0M	$41.8M	$22.9M	$20.5M
Operating Income (Loss)	-$70.4M	-$56.0M	-$41.8M	-$22.9M	-$20.5M
Interest Expense	—	—	—	—	$0.00
Nonoperating Income (Expense)	$2.0M	$4.2M	$783.0K	$2.0M	$188.0K
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$68.5M	-$51.8M	-$41.1M	-$20.9M	-$20.3M
Earnings Per Share, Basic	-$1.33	-$1.01	-$2.26	-$2.72	—
Earnings Per Share, Diluted	-$1.33	-$1.01	-$2.32	-$2.72	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$132.7M	$123.7M	$152.4M	$42.6M	$11.0M
Assets, Current	$128.7M	$104.9M	$152.1M	$42.0M	$10.5M
Cash and Cash Equivalents, at Carrying Value	$70.4M	$16.0M	$150.4M	$41.0M	$10.0M
Inventory, Net	—	—	—	—	—
Liabilities	$11.7M	$7.5M	$2.9M	$16.5M	$3.6M
Liabilities, Current	$9.6M	$5.2M	$2.5M	$2.0M	$3.2M
Long-term Debt	—	—	—	$14.0M	$0.00

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$57.4M	-$44.5M	-$39.6M	-$20.4M	-$24.2M
Net Cash Provided by (Used in) Investing Activities	$48.7M	-$101.5M	-$101.5M	—	$0.00
Net Cash Provided by (Used in) Financing Activities	$63.0M	$11.6M	$149.0M	$51.5M	$22.6M
Payments to Acquire Property, Plant, and Equipment	—	$153.0K	$153.0K	—	—
Payments for Repurchase of Common Stock	$3.0K	$3.0K	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)